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Abstract
In spite of the well-known clustering of multiple autoimmune disorders in families, analyses of specific shared genes and
polymorphisms between systemic lupus erythematosus (SLE) and other autoimmune diseases (ADs) have been limited.
Therefore, we comprehensively tested autoimmune variants for association with SLE, aiming to identify pleiotropic genetic
associations between these diseases. We compiled a list of 446 non–Major Histocompatibility Complex (MHC) variants
identified in genome-wide association studies (GWAS) of populations of European ancestry across 17 ADs. We then tested
these variants in our combined Caucasian SLE cohorts of 1,500 cases and 5,706 controls. We tested a subset of these
polymorphisms in an independent Caucasian replication cohort of 2,085 SLE cases and 2,854 controls, allowing the
computation of a meta-analysis between all cohorts. We have uncovered novel shared SLE loci that passed multiple
comparisons adjustment, including the VTCN1 (rs12046117, P = 2.02610206) region. We observed that the loci shared
among the most ADs include IL23R, OLIG3/TNFAIP3, and IL2RA. Given the lack of a universal autoimmune risk locus outside
of the MHC and variable specificities for different diseases, our data suggests partial pleiotropy among ADs. Hierarchical
clustering of ADs suggested that the most genetically related ADs appear to be type 1 diabetes with rheumatoid arthritis
and Crohn’s disease with ulcerative colitis. These findings support a relatively distinct genetic susceptibility for SLE. For
many of the shared GWAS autoimmune loci, we found no evidence for association with SLE, including IL23R. Also, several
established SLE loci are apparently not associated with other ADs, including the ITGAM-ITGAX and TNFSF4 regions. This
study represents the most comprehensive evaluation of shared autoimmune loci to date, supports a relatively distinct non–
MHC genetic susceptibility for SLE, provides further evidence for previously and newly identified shared genes in SLE, and
highlights the value of studies of potentially pleiotropic genes in autoimmune diseases.
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Introduction
Systemic lupus erythematosus (SLE [MIM 152700]) is a chronic
and severe systemic autoimmune disease characterized by the
production of high titers of autoantibodies directed against native
DNA and other cellular constituents. It is a prototypic autoim-
mune disease with heterogeneous clinical manifestations that may
involve many different organs and tissues, including skin, kidney,
lungs, heart, and brain. The prevalence of SLE in the U.S. is
estimated to be between 0.05% and 0.1% of the population,
disproportionately affecting women and African Americans
(0.009% of white men, 0.066% of white women, 0.038% of
African-American men, and 0.282% of African-American women)
[1]. A genetic etiology for SLE is unequivocal, as recent genome-
wide association studies (GWAS) have identified nearly 40
validated susceptibility loci and implicated a broad array of
biological pathways [2]. Nevertheless, recent estimates suggest that
these risk loci collectively explain between 8%–15% of the genetic
risk for SLE [3,4], highlighting the fact that much of the heritable
basis for SLE remains to be identified.
The clustering of multiple autoimmune diseases (ADs) within
families, including families with SLE [5,6], suggests some degree of
common genetic susceptibility [7–9]. This genetic overlap is
exemplified by the well-known associations of certain Human
Leukocyte Antigen (HLA) loci with multiple human ADs, as well
as non-HLA risk loci in diverse pathways such as IL2RA, STAT4,
PTPN22 and IFIH1 [10]. This phenomenon where a single
mutation or gene can affect multiple traits is known as pleiotropy.
Murine studies have similarly identified many susceptibility loci
that are shared across different autoimmune mouse models [11].
However, evidence for specific shared risk variants is modest, and
consequently the genetic mechanisms that may explain the
patterns of disease aggregation remain unclear.
To date, there is no large-scale, comprehensive assessment of
the genetic overlap between SLE and other ADs. Multiple genes
have been reported to be associated with both SLE and other ADs,
but analyses of such shared autoimmune loci have been limited to
specific loci and few diseases (reviewed in [12]). Criswell et al. [13]
analyzed a collection of 265 multiplex families with at least two
ADs. Based on findings concerning PTPN22, they suggest that
multiple sclerosis (MS) may have a pathogenesis that is distinct
from SLE, rheumatoid arthritis (RA) and type 1 diabetes (T1D).
Several genome-wide association studies (GWAS) have been
conducted in multiple ADs, providing an opportunity to assess
genetic similarity at the genome-wide scale. These include studies
of SLE, RA, T1D, MS, ankylosing spondylitis (AS), inflammatory
bowel disease (IBD), Crohn’s disease (CD), ulcerative colitis (UC),
celiac disease (CelD), psoriasis (PS), psoriatic arthritis (PsA),
juvenile idiopathic arthritis (JIA), Kawasaki disease (KA), systemic
sclerosis (SScl), sarcoidosis (SA), vitiligo (VI), alopecia areata (AA)
and Behc¸et’s disease (BeD). Several studies have evaluated
pleiotropic effects between two or three diseases, but have been
limited to a few dozen variants in a few loci [14–18]. Exceptions
include that of Sirota et al. [19], which used over 500 SNPs to
analyze allele-specific similarities and differences across six ADs,
and Thompson et al. [20], which evaluated the association of over
500 reported autoimmune loci with JIA. Wang et al. [21] similarly
performed a genome-wide comparative analysis of CD, UC and
T1D, and Festen et al. [22] of CD and CelD. Only Cotsapas et al.
[23] have recently analyzed shared variation of 107 immune SNPs
between seven Ads including SLE.
In order to assess the genetic overlap between SLE and other
ADs, potentially unveiling novel contributors to SLE pathogenesis,
we comprehensively tested all non-HLA variants implicated in
other ADs through large GWA approaches with P,1.061025, in
a large SLE cohort consisting of 1500 cases and 5706 controls [24–
27]. The primary advantages of this approach include the
opportunity to identify consistent or contrasting allelic risk, the
potential to more clearly identify common pathways, and a more
focused, narrow hypothesis space that generates more statistical
power due to fewer statistical tests. We did not include MHC
variants because they were not reported in all the GWAS. The
comparison and contrast of shared and distinct AD risk loci
provide the potential to improve diagnosis and prognosis and help
identify plausible pharmacological targets. Our data suggests that,
compared to other ADs, SLE exhibits modest overlap of associated
loci with other ADs. We have also uncovered novel shared SLE
loci. This study helps better understand the non-MHC genetic
architecture of ADs. Identification of novel SLE genes and shared
genetic pathways can contribute to a better understanding of
common genetic mechanisms, and eventually the development of
improved diagnosis, prognosis and targeted therapies.
Results
We compiled a list with 446 non-Major Histocompatibility
Complex (MHC) variants identified as significant in 74 Caucasian
GWAS of 17 autoimmune diseases (ADs) (Table 1) using a
publically available database [28]. Please see Materials and
Methods for further details regarding the selection of the AD
variants. Note that for the results herein discussed, we have
excluded loci reported from joint analyses of particular ADs, such
as the combined phenotype of inflammatory bowel disease (see
Materials and Methods). While this may exclude legitimate shared
risk loci, it was done so as not to structurally impose a greater
degree of genetic overlap amongst the handful of ADs that have
been directly analyzed together. Based on a block partitioning
approach using LD estimated from the CEU sample of the
International HapMap Project, we then mapped these SNPs to
337 genomic regions.
In order to identify novel SLE loci and assess the extent of
pleiotropy between SLE and other ADs, we tested the 446
aforementioned non-MHC variants for association with SLE in a
Author Summary
It is well known that multiple autoimmune disorders
cluster in families. However, all of the genetic variants that
explain this clustering have not been discovered, and the
specific genetic variants shared between systemic lupus
erythematosus (SLE) and other autoimmune diseases (ADs)
are not known. In order to better understand the genetic
factors that explain this predisposition to autoimmunity,
we performed a comprehensive evaluation of shared
autoimmune genetic variants. First we considered results
from 17 ADs and compiled a list with 446 significant
genetic variants from these studies. We identified some
genetic variants extensively shared between ADs, as well
as the ADs that share the most variants. The genetic
overlap between SLE and other ADs was modest. Next we
tested how important all the 446 genetic variants were in
our collection with a minimum of 1,500 SLE patients.
Among the most significant variants in SLE, the majority
had already been identified in previous studies, but we
also discovered variants in two important immune genes.
In summary, our data identified diseases with common
genetic risk factors and novel SLE effects, and this supports
a relatively distinct genetic susceptibility for SLE. This study
helps delineate the genetic architecture of ADs.
Analysis of Shared Autoimmune Variants
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large cohort of 1500 SLE cases and 5706 controls. This cohort
consists of the joint-analysis of previously described cohorts [24–
27], which haven’t previously been analyzed together. Of the 424
available SNPs based on direct genotyping or imputation, 237
(55.9%) met all quality control criteria. We employed a simple
strategy to address the multiple testing issue: we computed a False
Discovery Rate (FDR)-adjusted P-value [28] in joint analysis
results (PFDR), and discarded any variants that did not meet a
FDR-adjusted P-value (that is, PFDR$0.05) as likely false positives.
Therefore, we herein report the unadjusted P-values in the joint-
analysis and only report variants that survived a FDR [29]
correction for the number of comparisons in the joint-analysis
(PFDR). We have also elected to report the genomic control (GC)-
adjusted P-value. Of the 237 SNPs that met quality control (QC)
criteria, 39 survived a FDR adjustment with P,0.05. If a variant
failed quality control criteria in the joint-analysis, but met them in
the Lupus Large Association Study (LLAS) replication cohort, we
report the LLAS cohort results, as indicated in the tables. Finally,
if a SNP met quality control criteria in all cohorts, we additionally
report the meta-analysis results.
Novel SLE loci
Our first goal was the identification of novel pleiotropic regions
associated with SLE. An intronic variant in the V-set domain
containing T cell activation inhibitor 1 (VTCN1) showed the smallest P-
value in the joint-analysis (rs12046117, P= 2.02610206,
PFDR= 5.33610
205) (Table 2). This variant was one of the most
significant reported in a GWAS of JIA [28]. Unfortunately, the
risk allele was not reported.
We have also observed association with the zinc finger, CCCH-type
with G patch domain (ZGPAT) region, identified in GWAS of CD and
UC [28]. The most significant SNP (rs2297441, P= 7.63610204,
PFDR= 8.22610
203) (Table 2) is located in both the 59 UTR of the
tumor necrosis factor receptor superfamily member 6B (TNFRSF6B) and the
39 UTR of the regulator of telomere elongation helicase 1 (RTEL1). The
risk allele is the same as the one reported in UC.
The CD40 gene, which was reported as significant in GWAS of
MS and RA [28], showed evidence for association at several
variants in linkage disequilibrium (LD) (r2.0.70), the most
significant being rs6074022 (P= 1.41610203, PFDR=1.24610
202)
(Table 2), upstream of CD40. The risk allele for this variant is the
same in SLE as the one reported in MS. All the variants lie within
a known CNV region.
The IL12A region, identified in GWAS of MS and CelD [28],
showed association with SLE at two variants not in LD with each
other (r2 = 0.04). The most significant association was with
rs17810546 (Pmeta = 9.39610
203) (Table 2), upstream of IL12A,
but the risk allele is different from that reported in CeID.
Shared SLE loci
One of our goals was to specifically evaluate pleiotropy between
SLE and other ADs. In Table 3 we report our most significant
findings in regions previously reported to be associated with SLE.
The ADs that reported a GWA P,1.061025 at any variant in
these regions are shown.
The IL10 locus, which has not been previously reported in our
independent SLE cohorts, has been reported in GWAS of T1D,
BeD, CD and UC [28]. The rs3024493 variant, which was
reported in two GWAS of UC, was significant in all cohorts
(Pjoint = 4.38610
205). The reported risk allele is the same as we
report. This is not a novel effect in SLE; although it has not been
reported in a GWAS of SLE, IL10 has been recently identified in a
large-scale replication study [3]. This locus harbors a known copy
number polymorphism/variation (CNV) (http://genome.ucsc.
edu).
Similarly, the IRF8 locus, which has not been previously
reported in our independent SLE cohorts nor been reported in a
GWAS of SLE, has also been identified in a large-scale replication
study [3]. This region has been reported in GWAS of MS and UC
[28]. The rs16940202 variant, which was reported in UC, showed
association with SLE (Pjoint = 4.76610
207), but the alleles show
opposing effects.
The KIAA1109 region also showed association (rs13119723,
Pmeta = 4.97610
205) (Table 3). This SNP was reported in a GWAS
of RA, where the risk allele is consistent with our study of SLE
[28]. Other SNPs in this region have also been reported in GWAS
of T1D and CelD [28]. Interestingly, this region is adjacent to the
IL2–IL21 region, where several SNPs have been reported in
GWAS of T1D, UC, CelD and AA. Variation in these regions has
never been reported to have met genome-wide significance in
SLE. Association has been reported in 200 Colombian patients for
a SNP in LD with rs13119723 (rs6822844; r2 = 0.71) [30].
Association with SLE has also been reported in two studies of
mixed ethnicities for other variants in IL2/IL21 that lack LD
(r2,0.30) with rs13119723 [31,32].
For the vast majority of SNPs in Table 3, there is consistency
between the SLE risk allele and that reported in other ADs. For
example, the IRF5 variant has the same risk allele as RA, and SScl,
and the TNFAIP3 variant has the same risk allele as in four
different GWAS of RA [27]. There are two variants that exhibit
opposite effects, namely in FCGR2A and IKZF1, with UC and CD,
respectively [28].
Table 1. Data compiled from published GWA studies of
autoimmune diseases (ADs).
Disease Number of
Associated
loci
Associated
SNPs GWAS
Alopecia areata (AA) 7 7 1
Ankylosing spondylitis(AS) 8 8 1
Juvenile idiopathic arthritis (JIA) 1 1 1
Behcet’s disease (BeD) 2 2 1
Celiac disease (CelD) 42 (53) 42 (55) 3 (5)
Crohn’s disease (CD) 79 (84) 103 (111) 9 (14)
Kawasaki disease (KA) 2 2 1
Multiple sclerosis(MS) 37 41 9
Psoriasis (PS) 27 30 6
Psoriatic arthritis (PsA) 2 2 1
Rheumatoid arthritis (RA) 39 (48) 42 (55) 7 (8)
Sarcoidosis (SA) 1 1 1
Systemic lupus erythematosus
(SLE)
31 36 5
Systemic sclerosis (SScl) 3 3 1
Type 1 diabetes (T1D) 56 64 8
Ulcerative colitis (UC) 59 (64) 77 (86) 6 (9)
Vitiligo (VI) 12 12 2
Counts in parentheses include GWAS of combined ADs including inflammatory
bowel disease (CD+UC), CelD+RA, CD+CelD, and CD+SA (see Materials and
Methods).
doi:10.1371/journal.pgen.1002406.t001
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Table 2. Association results in novel pleiotropic regions associated with SLE.
Joint-Analysis Meta-Analysis
SNP1 Ch Pos (Mb)
MAF
case
MAF
control MA P-value2
GC P-
value
FDR P-
value OR [95%CI] P-value2 OR [95%CI] Region
Diseases
associated
with region
in GWAS3
rs12046117SMU 1 117.463 0.07 0.01 T 2.02E-06d 2.15E-06 5.33E-05 1.65[1.34–2.03] NA NA VTCN1 JIA
rs6738825SMU 2 198.722 0.45 0.48 G 3.12E-03d 3.32E-03 2.12E-02 0.82[0.72–0.94] NA NA PLCL1 CD
rs17810546M 3 161.148 0.10 0.11 G 2.47E-03 2.63E-03 1.89E-02 0.82[0.72–0.93] 9.39E-03 0.89[0.81–0.97] IL12A MS, CelD
rs7672826 4 182.775 0.31 0.33 G 1.90E-03d 2.02E-03 1.56E-02 0.83[0.74–0.93] NA NA RPL19P8 MS
rs881375SMU 9 120.732 0.36 0.33 T 3.89E-03 4.14E-03 2.49E-02 1.14[1.04–1.24] NA NA VEGFA UC, CD
rs1953126SMU 9 120.720 0.36 0.33 T 2.93E-03d 3.12E-03 2.17E-02 1.20[1.06–1.35] NA NA TRAF1 RA, CelD
rs7221109SU 17 36.024 0.41 0.38 T 2.21E-03d 2.35E-03 1.74E-02 1.21[1.07–1.36] NA NA CCR7 T1D
rs6074022SM 20 44.174 0.28 0.26 C 1.41E-03r 1.50E-03 1.24E-02 1.45[1.15–1.82] NA NA CD40 RA, MS
rs2297441SU 20 61.798 0.20 0.23 G 7.63E-04 8.11E-04 8.22E-03 0.84[0.76–0.93] NA NA ZGPAT UC, CD
Only the most significant variant in each region is presented. All variants met a FDR-adjusted threshold of significance in the joint-analysis (FDR P,0.05), as described in
the Materials and Methods. The genomic control-adjusted (GC) P-value is also shown. When both joint and LLAS1 results available, a meta-analysis between all cohorts
is presented. The smallest P-value is presented and, unless noted otherwise, it is under the additive model. OR and CI calculated under the model presented.
Ch – chromosome; Mb – Megabases; MA – minor allele; MAF – Minor allele frequency; OR – odds ratio; CI – confidence interval; NA – not available.
1The initials after the marker denote that this marker was imputed in a cohort: SSLEGEN, MMN, UUCSF.
2The superscript after the P-value denotes its genetic model, when other than the additive: ddominant, rrecessive.
3Diseases that reported any associated SNP with P-value,1.061025 in the regions indicated (not necessarily the same SNP reported in this table) through the GWA
approach [28].
Disease abbreviations are the same as for Table 1.
doi:10.1371/journal.pgen.1002406.t002
Table 3. Shared loci: Association results for SLE susceptibility loci associated with another autoimmune disease.
Joint-Analysis* Meta-Analysis
SNP1 Ch Pos (Mb)
MAF
case
MAF
control MA P-value2
GC P-
value
FDR P-
value OR[95%CI] P-value2 OR[95%CI] Region
Diseases
associated
with region
in GWAS3
rs10800309* 1 159.739 0.30 0.33 A 5.03E-05 5.35E-05 NA 0.85[0.78–0.92] NA NA FCGR2A UC
rs3024493SMU 1 205.011 0.18 0.15 C 4.38E-05 4.66E-05 6.48E-04 1.26[1.13–1.41] NA NA IL10 T1D, CD, UC,
BeD
rs6445975M 3 58.345 0.32 0.29 T 4.51E-04 4.79E-04 5.09E-03 1.18[1.07–1.29] 5.27E-09 1.20[1.13–1.27] PXK SLE
rs13119723MU 4 123.438 0.11 0.13 G 5.56E-03d 5.91E-03 3.47E-02 0.82[0.71–0.94] 4.97E-05d 0.83[0.76–0.91] KIAA1109 RA, T1D,
CelD
rs11747270SMU 5 150.239 0.05 0.02 G 1.12E-03d 1.19E-03 1.15E-02 1.39[1.14–1.70] NA NA IRGM CD
rs5029939S 6 138.237 0.06 0.03 G 1.51E-14d 1.61E-14 8.94E-13 2.40[1.92–3.00] NA NA TNFAIP3 RA, CelD, UC,
PS, SLE
rs1456893S 7 50.204 0.33 0.30 G 3.01E-03 3.20E-03 2.10E-02 1.14[1.05–1.25] NA NA IKZF1 CD
rs10488631M 7 128.381 0.19 0.11 T 2.55E-27 2.71E-27 6.05E-25 1.97[1.74–2.22] NA NA IRF5 RA, SLE, UC,
SScl
rs2618476SU 8 11.390 0.30 0.25 T 1.10E-07 1.17E-07 4.34E-06 1.29[1.18–1.42] NA NA BLK SLE, RA
rs16940202SMU 16 84.572 0.09 0.02 T 4.76E-07 5.06E-07 1.41E-05 1.53[1.30–1.81] NA NA IRF8 UC, MS
rs181359M 22 20.27 0.22 0.18 T 3.37E-06 3.58E-06 7.27E-05 1.28[1.15–1.41] 1.15E-09 1.23[1.15–1.33] UBE2L3 CD, SLE
Only the most significant variant in each region is presented. All variants met a FDR-adjusted threshold of significance in the joint-analysis (FDR P,0.05), as described in
the Materials and Methods. The genomic control-adjusted (GC) P-value is also shown. When both joint and LLAS1 results available, a meta-analysis between all cohorts
is presented. The smallest P-value is presented and, unless noted otherwise, it is under the additive model. OR and CI calculated under the model presented.
Ch – chromosome; Mb – Megabases; MA – minor allele; MAF – Minor allele frequency; OR – odds ratio; CI – confidence interval; NA – not available.
*This marker failed quality control or was unavailable in the joint-analysis, here we are presenting the LLAS results.
1The initials after the marker denote that this marker was imputed in a cohort: SSLEGEN, MMN, UUCSF.
2The superscript after the P-value denotes its genetic model, when other than the additive: ddominant, rrecessive.
3Diseases that reported any associated SNP in Caucasians with P-value,1.061025 in the regions indicated (not necessarily the same SNP reported in this table) through
the GWA approach [28].
Disease abbreviations are the same as for Table 1.
doi:10.1371/journal.pgen.1002406.t003
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SLE–specific loci
In addition to significant associations in regions previously
implicated in other ADs, we have also identified significant
associations in established SLE regions that do not meet a GWA
P,1.061025 in other ADs. Table 4 shows the established SLE-
specific variants and their association results in our combined
cohorts. These variants have not been reported in GWAS of any
AD except SLE, hence suggesting that these may be SLE-specific
genetic risk factors or that their magnitude of effect in other ADs is
more modest. Established SLE loci that are not strongly associated
with other ADs include the integrin-aM (ITGAM), tumor necrosis factor
superfamily member OX40L (TNFSF4), pituitary tumor-transforming 1
(PTTG1), PHD and ring finger domains 1 (PHRF1), WDFY family
member 4 (WDFY4), and B-cell scaffold protein with ankyrin repeats 1
(BANK1) regions.
With the exception of BANK1, all of these effects have been
previously reported based on individual analyses of the cohorts
considered here.
Autoimmune loci not associated with SLE
Our study was well powered to detect effect sizes (as measured
by the odds ratio (OR)) similar to those reported in other ADs.
Under the assumptions described in the Materials and Methods,
we were powered to detect: OR.1.45 for variants with minor
allele frequency (MAF) = 0.05, OR.1.30 for variants with
MAF=0.10, or OR.1.20 for variants with MAF.0.30. The
power for each of the SNPs herein reported is shown in Table S1.
For many of the shared GWAS autoimmune loci we found no
evidence for association with SLE in these cohorts. We scrutinized
all variants that met QC criteria and whose smallest P-value was
P.0.05 in any (joint-, replication- , or meta-) analysis. Amongst
the loci shared between the most diseases, we found no evidence of
association for IL23R, FASLG, REL, IL18RAP, MST1, RBPJ, IL7R,
PTGER4, BACH2, PVT1, PTPN2, and C1QTNF6 regions.
As in all studies a definitive answer is not possible for all loci.
Specifically, we note that in several of the AD loci shared between
the largest number of diseases, we did not find SNPs that met the
FDR-adjusted threshold in the joint-analysis, but met all the QC
criteria and had an unadjusted P-value,0.05: these include
SPRED2 (rs934734, P = 1.41610202), AFF3 (rs10865035,
P= 3.04610202), CTLA4 (rs3087243, P = 1.66610202), IL12B
(rs2082412, P= 1.02610202), IL2RA (rs12251307, P = 2.216
10202), LRRC32 (rs7927894, P= 2.32610202), C14orf81 (rs4899
260, P= 1.48610202), and GSDMB (rs8067378, P= 2.17610202).
Further work is necessary to determine if these loci contribute
modestly or conditionally to the risk of SLE.
Shared autoimmune loci
An important goal of our study was to assess the extent of
pleiotropy between all 17 ADs using their reported GWAS results.
Figure 1 shows the loci shared between GWAS of ADs. The
regions shared across the largest number of ADs include IL2RA
(MS, T1D, RA, VI, AA and CD), IL23R (CD, UC, PS, BeD and
AS), OLIG3/TNFAIP3 (RA, PS, SLE, UC, and CelD), PTPN22
(CD, RA, T1D, and VI), IL10 (CD, T1D, UC, and BeD), and an
intergenic region between ZPBP2 and GSDMB (CD, RA, UC, and
T1D).
We also sought to better understand the relationships among
different diseases given the common and unique regions reported
in their respective GWAS. In order to identify which diseases
cluster together based on the reported shared regions (i.e., binary
yes/no), we performed hierarchical clustering analysis of ADs also
including reported risk loci from 4 control traits/diseases including
height, breast cancer, coronary heart disease, and bipolar disorder
(Figure 2). This analysis provides a visual characterization of the
similarities among diseases based on the number of shared regions.
The diseases that share the largest number of genomic regions
include CD and UC (BSN/APEH/MST1, C11orf30/LRRC32,
C1orf81/KIF21B, CARD9, DAB2/PTGER4, GOT1/NKX2-3, IL10,
IL23R, NAIP1/CYCSP42, PUS10, RCL1/JAK2, TNFSF15, ZGPAT,
ZPBP2/GSDMB), followed by T1D and RA (AFF3/LONAF2,
C4orf52/RBPJ, CTLA4, DKFZp667F0711, IL2RA, KIAA1109,
PTPN22, RPS2P14/RSBN1, SH2B3/ATXN2, UBASH3A, ZPBP2/
GSDMB).
We observed that SLE shares the largest number of loci with
RA (FAM167A/BLK, IRF5/TNP03, and STAT4). It is noteworthy
that SLE appears isolated from the other ADs (i.e., shares the least
with the other ADs despite being among the ADs with the most
Table 4. SLE–specific loci: Association results for established SLE–specific regions in our joint cohorts.
Joint-Analysis* Meta-Analysis
SNP1 Ch Pos (Mb)
MAF
case
MAF
control MA P-value2 GC P-value
FDR P-
value OR [95%CI] P-value2 OR [95%CI] Region
rs10798269M 1 170.041 0.31 0.36 G 2.02E-05 2.15E-05 3.42E-04 0.83[0.76–0.90] 4.04E-10 0.83[0.78–0.88] TNFSF4
rs10516487 4 103.108 0.27 0.32 G 4.88E-05 5.19E-05 6.81E-04 0.83[0.76–0.91] NA NA BANK1
rs2313132 4 139.050 0.13 0.11 G 2.93E-03 3.12E-03 2.11E-02 1.21[1.07–1.38] NA NA SLC7A11
rs2431697* 5 159.813 0.39 0.44 G 9.68E-08 1.03E-07 NA 0.80[0.74–0.87] NA NA PTTG1
rs11101442SU 10 49.606 0.30 0.34 T 4.16E-05 4.42E-05 6.57E-04 0.83[0.76–0.91] NA NA WDFY4
rs7927370M 11 54.893 0.04 0.06 T 1.13E-03 1.20E-03 1.12E-02 0.74[0.62–0.89] NA NA OR4A51
rs4963128* 11 0.58 0.30 0.35 A 7.77E-07 8.26E-07 NA 0.81[0.74–0.88] NA NA PHRF1
rs11150610 16 31.242 0.37 0.43 C 1.16E-08 1.23E-08 5.51E-07 0.79[0.72–0.85] NA NA ITGAM
Only the most significant variant in each region is presented. All variants met a FDR-adjusted threshold of significance in the joint-analysis (FDR P,0.05), as described in
the Materials and Methods. The genomic control-adjusted (GC) P-value is also shown. When both joint and LLAS1 results available, a meta-analysis between all cohorts
is presented. The smallest P-value is presented and, unless noted otherwise, it is under the additive model. OR and CI calculated under the model presented.
Ch – chromosome; Mb – Megabases; MA – minor allele; MAF – Minor allele frequency; OR – odds ratio; CI – confidence interval; NA – not available.
*This marker failed quality control or was unavailable in the joint-analysis, we are presenting the LLAS results.
1The initials after the marker denote that this marker was imputed in a cohort: SSLEGEN, MMN, UUCSF.
2The superscript after the P-value denotes its genetic model, when other than the additive: ddominant, rrecessive.
doi:10.1371/journal.pgen.1002406.t004
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identified risk loci). In contrast, despite only having 12 reported
loci, VI clusters more closely with other ADs, suggesting more
genetic overlap. However, we strongly caution against over-
interpretation of this clustering result, as bootstrapping only
revealed strong statistical support (Bootstrap Probability Val-
ue$0.95) for differentiating height from the ADs and the other
control diseases (see Materials and Methods).
Discussion
The clustering of multiple autoimmune disorders in families and
evidence for autoimmune pleiotropic loci are well known.
Nevertheless, no comprehensive assessment of the specific shared
variants between SLE and other autoimmune diseases (ADs) has
yet been performed in a single large-scale study based on GWAS
data. Analyses of shared SLE loci have been limited to specific loci
and few diseases (reviewed in [12]). In this study we used findings
from published GWAS to assess the extent of genetic overlap
between SLE and seventeen autoimmune diseases, testing if
variants implicated in other ADs show association in our large
SLE cohort. Given that the MHC is unquestionably a universal
risk region for autoimmunity, and some GWAS did not report
their results in this region, we excluded HLA loci from our
analyses.
The loci that were associated with the largest number of ADs
include IL23R, TNFAIP3, and IL2RA, supporting an important
role for T cell and innate immune response pathways in
autoimmunity. Nevertheless, these loci are not implicated in all
ADs, suggesting that, with the exception of the HLA region, there
seem to be no universal genetic risk factors for autoimmunity. It is
commonly accepted that there is a common genetic background
predisposing to autoimmunity and inflammation, and that further
combinations of more disease-specific variation at HLA and non-
HLA genes, in interaction with epigenetic and environmental
Figure 1. Shared loci between GWAS of ADs. Gene regions are below each chromosome, diseases where it was reported are above, represented
by a colored circle.
doi:10.1371/journal.pgen.1002406.g001
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factors, contribute to disease and its clinical manifestations [33].
Our data additionally suggests that, instead of resulting from
common risk factors, autoimmunity may result from specific and
multiple different pleiotropic effects. This is consistent with a
recent report showing that genomic pleiotropy is relatively low, as
most genes affect only a small number of traits [34]. The authors
suggest that genes displaying a high degree of pleiotropy also
exhibit an individually larger effect on each trait [34]. It is likely
that different population genetic factors (e.g., natural selection,
migration/isolation, random mutation) in similar or distinct
environments led to the establishment of different autoimmune
loci and subsequent migrations and interbreeding have led to the
current plethora of loci that predispose to autoimmunity.
Based on our analyses of shared non-HLA loci across ADs, the
most genetically similar diseases appear to be CD with UC, and
T1D with RA, sharing 15 and 11 loci, respectively. While the
former pair is clearly supported by overlapping clinical manifesta-
tions, since both CD and UC are subsets of IBD, the overlap
between the latter pair is not entirely clear based on their organ
involvement. The clustering patterns do not seem biased by the
number of reported loci for each disease. As such, while the genetic
overlap between CD and UC may reflect the prevalence of more
specific IBD genes, the genetic overlap between T1D and RA may
reflect the existence of general, nonspecific autoimmunity genes.
Despite being a prototypic AD, the non-HLA genetic overlap
between SLE and the ADs herein investigated is more modest
than we anticipated. The disease with which it shares the most loci
is RA, which is potentially interesting due to the common clinical
presentation of arthritis. The number of reported SLE loci is
similar to other ADs and does not explain its relative distance from
other ADs. The clinical heterogeneity of SLE may, at least in part,
account for the relatively modest number of shared loci. Different
SLE loci are likely differentially associated with specific clinical
criteria, as was recently shown in GWAS of anti-RNA binding
proteins [35], and anti–dsDNA autoantibody production [36] in
SLE. It should also be noted that SLE may share more loci with
systemic diseases not included or not well represented in our
analyses. Our data included 49 loci reported for RA, two for BeD,
three for SScl, but Sjo¨gren’s syndrome and antiphospholipid
syndrome lack GWAS. Interestingly, two of the three loci reported
in the GWAS of SScl, IRF5 and STAT4, also show association in
GWAS of SLE. Similarly, Anaya et al. [37] recently analyzed the
association of the SLE predisposing risk variant (rs1143679) for
ITGAM-ITGAX across 7 other ADs, only showing a suggestive
association for SScl. For many of the shared GWAS autoimmune
loci we found no evidence for association with SLE, including for
IL23R, in spite of having enough power to detect the effects
reported in other diseases. Although we cannot exclude the
Figure 2. Hierarchical clustering of ADs and four non-ADs. Analysis was restricted to diseases with .10 reported loci in their GWA studies, to
associations reported from populations of European ancestry, and excluded those reported from the aggregate phenotype of IBD, as well as those
with MS severity or age of onset. Dendrogram and heatmap are shown.
doi:10.1371/journal.pgen.1002406.g002
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possibility that 1) other variants in these loci predispose to SLE, or
2) that these loci have weaker effects in SLE implying a potential
lack of statistical power, or 3) that their effects are conditional on
other unknown loci, it is plausible that the lack of these common
genetic factors contributes to SLE being a distinct disease. Also,
several established SLE loci are apparently not associated with
other ADs, including the ITGAM-ITGAX region, TNFSF4,
PTTG1, PHRF1, WDFY4 and BANK1 regions. Obviously, these
risk variants may simply have weaker effects in other ADs and the
studies lacked power to detect them. This situation was recently
illustrated in a meta-analysis of CD and CelD, where the increased
power of the combined datasets allowed the detection of shared
loci with a relatively small effect, hence undetectable in the
individual diseases [22].
Our analyses identify novel shared SLE loci. The results that we
report were adjusted for the number of comparisons, which
decreases the likelihood of a false positive result. The V-set domain
containing T cell activation inhibitor 1 (VTCN1) region, which has been
reported in a GWAS of JIA, showed the strongest novel
association with SLE. Evidence suggests that this gene plays a
role in the negative regulation of T cell responses. The zinc finger
ZGPAT region also shows a significant association with SLE.
Despite being clearly strong candidates because of their association
with other ADs, the new SLE loci require validation. It is worth
noting that we discovered associations consistent with and in
contrast to the same risk allele in other ADs. This observation was
recently confirmed by Wang et al. [34], who suggests that
susceptibility loci involved in the pathogenesis of ADs may have
antagonistic pleiotropic effects, where risk alleles for one disease
may confer selective advantage for another disease or infection
resistance. Given that the functional variant is not known, we
cannot rule out that the inverse association arises from different
LD patterns.
A limitation of our study is the fact that we restricted our
analyses to variants reported from GWAS in populations of
European Ancestry. Although we have certainly missed shared
variants identified in large candidate gene studies or targeted
meta-analyses, many ADs lack such studies. Thus, given the
increasing coverage of the genome with modern SNP chips, we
preferred to restrict our analyses to a directly comparable set of
results based on GWAS. These agnostic scans help to minimize
the extent of potential methodological and publication biases. We
should note that our analyses do not provide an unbiased estimate
of the total degree of genetic overlap amongst ADs, given that the
application of stringent significance thresholds in GWAS certainly
overlooks true risk loci. Future studies using all variants in these
GWAS will be required to directly estimate the degree of shared
susceptibility. Finally, it is important to note that some of the
genetic overlap with SLE may have been missed in our analyses
because a large proportion of candidate SNPs failed our quality
control thresholds, and thus could not be effectively tested for
association in our samples.
Much remains to be done before the genetic etiology of the
autoimmunity spectrum is resolved. Continued studies of popu-
lations beyond those of European ancestry are certainly needed. A
catalog of all shared and distinct risk loci requires that these
regions be thoroughly resequenced in suitably large population
samples, with additional genotyping of the resulting comprehen-
sive set of variants in order to confirm and fully characterize the
extent of genetic risk. The examination of the patterns observed
here generates an appreciation for potential interplay between
population genetic factors (e.g., natural selection, migration) and
environmental factors and calls for the interrogation of these loci
in significant numbers of samples from different ethnic popula-
tions.
This study represents the most comprehensive evaluation of
shared autoimmune loci to date. In addition, we provide further
evidence for previously and newly identified pleiotropic genes in
SLE. These findings support a relatively distinct genetic
susceptibility for SLE, a genetic basis for the shared pathogenesis
of ADs, and the value of studies of potentially pleiotropic genes in
autoimmune diseases.
Materials and Methods
Ethics statement
Written informed consent was obtained from all study
participants and the institutional review board at each collaborat-
ing center approved the study.
Autoimmune disease loci
We constructed a list of reported risk variants for ADs using
data from the National Human Genome Research Institute’s
Catalog of Published Genome-Wide Association Studies (http://
www.genome.gov/gwastudies) accessed on June 4th, 2011 [28].
Briefly, this database contains all identified SNPs with
P,1.061025 from GWAS that attempted to assay at least
100,000 SNPs in the initial analysis stage, thus excluding studies
focused on candidate genes. We extracted any reported risk
variants for the following ADs: SLE, rheumatoid arthritis (RA),
type 1 diabetes (T1D), ankylosing spondylitis (AS), Crohn’s disease
(CD), ulcerative colitis (UC), celiac disease (CelD), multiple
sclerosis (MS), systemic sclerosis (SScl), psoriasis (PS), psoriatic
arthritis (PsA), juvenile rheumatoid arthritis (JIA), Kawasaki
disease (KA), sarcoidosis (SA), vitiligo (VI), alopecia areata (AA)
and Behc¸et’s disease (BeD). Given that not all of these GWAS
reported their Major Histocompatibility Complex (MHC) or
Human Leukocyte Antigen (HLA) results, we opted for excluding
this region, in order to avoid biases due to missing HLA data from
some studies. We excluded inflammatory bowel disease and MS
severity or age of onset, and have only included results published
in samples of European ancestry. After removing SNPs that map
to the MHC and those with reported associations based on
haplotypes, our final list of reported risk variants included 446
SNPs. We then mapped these SNPs to genomic regions using a
block partitioning approach [38], based on LD-information
estimated from the CEU (Utah residents with ancestry from
northern and western Europe) sample of the International
HapMap Project.
Clinical samples
Samples used in this study have been previously described [24–
27]. Briefly, we combined 743 SLE cases and 3566 controls from
the International Consortium for Systemic Lupus Erythematosus
Genetics (SLEGEN; www.slegen.org) GWAS [25], with 244 SLE
cases and 2140 controls from the Minnesota (MN) cohort GWAS
[24], and with 513 SLE cases from the University of California
San Francisco (UCSF) Lupus Genetics Project [26,27]. These 513
cases were included and are also described in a GWAS of SLE
[39]. Exclusion of duplicates and first-degree relatives yielded a
total sample of 1500 cases and 5706 controls. Quality control was
performed as described [25]. We included males and females of
European ancestry.
In addition, we used data from the Lupus Large Association
Studies (LLAS) [25], when available, as a replication cohort. The
LLAS replication study consists of an independent cohort of 2085
SLE cases and 2854 controls, and was used to replicate 8230 SNPs
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from the SLEGEN GWAS [25]. This study consists of males and
females of European ancestry.
Statistical analysis
Genotypes from all subjects were imputed using the program
IMPUTE [40] version 0.5 for SNPs not genotyped or poorly
genotyped. Imputation was performed using high quality genotype
data from the corresponding study (SLEGEN, MN and UCSF)
and phased HapMap Phase II (NCBI B35 assembly) genotype
data from 60 CEU HapMap founders. We used SNPs that met the
following quality criteria: 1) no statistically significant differences in
the proportions of missing genotype data between cases and
controls (i.e., P.0.05); 2) overall ,10% missing genotype data; 3)
Hardy-Weinberg Expectations (HWE) in controls P.0.01, HWE
in cases P.0.0001; and 4) minor allele frequencies (MAFs) of
controls within a 95% or 99.99% confidence interval for ethnicity
matched HapMap MAFs, for genotyped and imputed SNPs,
respectively. Retained SNPs had an estimated MAF.0.01 in the
control samples, an information score .0.50 and a confidence
score .0.90. Imputed SNPs were analyzed using SNPTEST with
probabilistic genotypes [40].
We combined the genotypic and imputed data from the three
cohorts described above and performed a joint- and a meta-
analysis. In the tables with the results we report which SNPs and
cohorts were imputed vs. directly genotyped. We used SNPs that
met the same quality criteria as described above. To account for
potential population stratification, we computed Principal Com-
ponents (PCs) and adjusted these analyses for four PCs, as
described [25]. The genome-wide inflation factor in the joint
analysis was l=1.15. We include the joint analysis of these loci
after applying quality control to each individual cohort as the joint
analysis can provide increased power for some genetic models for
more modest allele frequencies (e.g., recessive model). From our
list with 446 autoimmune SNPs, 424 total unique SNPs were
genotyped or imputed in our SLE cohorts. Of these, 237 (55.9%)
met our QC thresholds, while 187 (44.1%) failed as follows: 6
(1.4%) have 10–20% missing genotype data, 1 (0.2%) have
MAF,0.01 in controls, 3 (0.7%) failed Hardy-Weinberg Equilib-
rium thresholds, 91 (21.5%) have .20% missing genotype data,
and /or have significant differences in missingness between cases
and controls, and 86 (20.3%) did not meet imputation QC
thresholds. We report uncorrected P-values, though we also
corrected for multiple comparisons using a False Discovery Rate
(FDR) procedure [29] for the 237 SNPs that passed QC. As such,
our multiple comparison strategy consisted of only selecting those
variants that met FDR significance, that is, with a FDR-adjusted
P-value,0.05. Although we computed the FDR-adjusted P-value
for the smallest P-value (under the additive, dominant or recessive
model), this smallest P-value is virtually always within one order of
magnitude different from the additive P-value, which is hence
comparable to computing the FDR for P-values under the same
model. We performed a weighted Z-score meta-analysis as
implemented in METAL (www.sph.umich.edu/csg/abecasis/met-
al), with weights being the square root of the sample size for each
dataset; thus, the meta-analysis incorporates direction, magnitude
of association and sample size. We report the minimum P-value
based on hypothesis tests considering additive, dominant and
recessive modes of inheritance; however, because these tests can be
affected by low genotype counts, we required at least 30
homozygotes for the minor allele to consider the recessive, and
15 to consider the additive model, otherwise the results under the
dominant model are reported. All genetic models were defined
relative to the minor allele. Associations with SLE susceptibility
were considered statistically significant if they met a FDR-adjusted
threshold of P,0.05.
We used Quanto (http://hydra.usc.edu/gxe/) to calculate the
power of our sample size. We assumed an additive genetic model,
population risk of 0.1%, and a=0.001.
In order to examine the global similarity between ADs based on
their reported risk loci (defined based on LD, as described above),
we performed a hierarchical clustering analysis of ADs with at least
10 reported loci (binary yes/no). ADs with less than 10 reported
loci were excluded as their lower count of reported loci may reflect
a less intensive assessment of genetic risk factors (i.e. fewer
genome-wide investigations often with smaller sample sizes). We
restricted the analysis to associations reported from populations of
European ancestry, and excluded those reported for MS severity
or age of onset. So as not to inform the clustering of ADs based on
the presence of joint analyses, we excluded associations from
studies of pooled phenotypes including IBD, RA with CelD, CD
with CelD, and CD with SA. This produced a final dataset of 330
loci reported across nine ADs. We also included loci reported from
the GWAS catalogue for 4 control diseases (height, breast cancer,
coronary heart disease, and bipolar disorder), similarly using LD
to define specific genomic loci. We computed the dissimilarity
between ADs and the control diseases using distance metric
appropriate for binary data, performing hierarchical clustering
using the hclust function for the R Statistical Programming
Language [41]. We evaluated the uncertainty in the clustering
analyses using a multiscale bootstrap resampling approach
implemented within the pvclust package for R [42].
Supporting Information
Table S1 First tier shows the SNPs presented in Table 2 of the
manuscript, followed by Table 3 in the middle and Table 4 at the
bottom. The power was computed in the joint-analysis of 1,500
cases and 5,706 controls, under the genetic model presented,
assuming a population risk of 0.1% and a=0.001. OR – odds
ratio; CI – confidence interval; MAF – Minor allele frequency.
The smallest P-value is presented and, unless noted otherwise, it is
under the additive model. OR and CI calculated under the model
presented. * The superscript after the P-value denotes its genetic
model, when other than the additive: ddominant, rrecessive.
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